Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06981546
Starting soon Observational

Modeling Clinical Outcomes in Gambling Addiction

NCT06981546 · tracked via the Priya Life Science France tracker
Sponsor
Hospices Civils de Lyon
Phase
Observational
Started
2025-09-01
Last updated
2025-05-20

Condition(s) studied

Gambling Disorder

Study summary

Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences.

MOGADOR is a longitudinal, multicentric, prospective, prognostic study, which aims to identify factors predicting the evolution of french patients with GD in care centers particularly involved in the management of GD. The main goal will focus on evolution of DSM-5 (Diagnostic and Statistical Manual of Mental Disorder 5th edition) GD criteria during the first year of follow-up. The prognostic factors will be collected at base-line and they will be considered to influence the long-term prognosis of patients.

For patients suffering of GD, our main hypothesis is that initial factors like individual socio-demographic characteristics, clinical psychiatric profiles, addiction comorbidities, and behaviour are associated with the clinical prognosis (total remission of DSM-5 criteria of GD at 12 months).

MOGADOR will be the first study, aiming to model prognostic aspects of GB in populations specially monitored for this disorder.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient, male or female, over 18 years old, consulting in one of the participating centers. * DSM-5 criteria for gambling disorder at inclusion: at least 4 criteria present in the 12 months preceding the study. * First treatment for gambling disorder or no treatment in the last 6 months (initiation or re-initiation of care). Exclusion Criteria: * Unable to be reached by phone. * Unable to use the internet. * Patient under antiparkinsonian treatment of the dopaminergic family. * Being treated with a drug that may trigger/increase symptoms of gambling disorder (e.g. dopamine agonist). * Subject under guardianship.

Primary outcome measure(s)

  • Partial remission of gambling disorder at 12 months (strictly less than 4 DSM-5 criteria) — DSM-5 criteria assessment will be conducted at 9 and 12 months after inclusion.
    Assessment of DSM-5 criteria will be performed by the clinician, and by a previously trained CRA if clinical follow-up is discontinued.
  • modeling prognostic factors — at inclusion visit.
    The prognostic factors, studied will be: number of initial DSM-5 criteria, gender, age, marital status, housing, employment status, socioeconomic level, time spent gambling, impulsivity, type of gambling, location of gambling, and also the factor with the strongest association in univariate analysis among the following factors: * Depression (PHQ scale), * Anxiety (GAD scale), * Quality of life (SF-36 scale).

Trial sites (9)

FacilityCityRegionStatus
Hôpital Jen Minjoz, CHU de Besançon Besançon France
Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier Bron France
Service Universitaire d'Addictologie de Lyon (SUAL), Groupement Hospitalier Est Bron France
Service Universitaire d'Addictologie, CHU de Clermont-Ferrand Clermont-Ferrand France
Name of location * Service d'Addictologie, Groupe Hospitalier Seclin Carvin Lille France
Centre Expert Régional du Jeu Pathologique (CERJeP Limousin) Limoges France
Service Universitaire d'Addictologie, CHU de Nîmes Nîmes France
Assistance Publique des Hôpitaux de Paris, Hôpital Marmottan Paris France
Hôpital de Bellevue, CHU de St-Etienne Saint-Etienne France

More Hospices Civils de Lyon trials in France

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief Recruiting
Validation of the French Version of the New Mobility Score (NMS) Recruiting
Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts Recruiting
Impact of Mental Health First Aid-trained Peers on the Mental Well-being of First-year Medical Residents. Active, not recruiting
Psychological Support Interventions for Women With Endometriosis (ENDOPSY) Starting soon

Other trials for the same condition

Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study Recruiting
Virtual Reality Exposure Therapy for Gambling Disorder Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06981546 on ClinicalTrials.gov ↗ ← All trials in France